Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
Mar 28, 2012, 04:26 ET
NEW YORK, March 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0804702/Urological-Disorders-Therapeutics-to-2017---Large-Number-of-Licensing-Deals-for-Approved-Products-Reflects-a-Pessimistic-RD-Future.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
Summary
GBI Research's new report, "Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future", provides in-depth analysis of the unmet need, drivers, and barriers that impact the global urological disorders market. The report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The global urological disorders market is growing rapidly with the increasing Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infection (UTI) diseased populations. In 2010, the global urological disorders market was estimated to be worth $8.1 billion, representing a CAGR of 7.9% between 2002 and 2010. The BPH market, with sales worth $4.1 billion in 2010, accounted for 50% of the total urological disorders market. The UI market was estimated to be $2.4 billion, the second largest urological disorders market, and to have grown at a CAGR of 6.2% between 2002 and 2010. By 2017, the global urological disorders market is forecast to be worth $10.3 billion, representing a CAGR of 3.4% between 2010 and 2017. BPH is expected to remain the largest market in the urological disorders segment with sales of $5.7 billion in 2017. The Research and Development (R&D) pipeline for urological disorders currently has 72 molecules in different stages of clinical development. The BPH R&D pipeline accounted for approximately 39% of the total urological disorders pipeline.
The global urological disorders market is very competitive, with the top five companies accounting for 88% of the total market in 2010. Johnson & Johnson leads the market with a share of 29%. Its two main drugs are Levaquin and Elmiron, which have strong presence in the UTI and Urinary Incontinence (UI) markets respectively.
The urological disorders market has witnessed strong deal activity between 2004 and 2011. The 120 deals conducted comprised M&A deals (44), licensing deals (67) and co-development deals (nine). This growth has driven M&A activities, primarily for companies looking to expand their product portfolio for indications such as BPH, UI, UTI and Interstitial Cystitis (IC).
The urological disorders market remains attractive and is set to see moderate growth between 2010 and 2017, despite many of its blockbuster drugs going off-patent during the period.
Scope
- Annualized market data for the urological disorders market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including UI, BPH, UTI and IC.
- Analysis of the urological disorders market in the leading geographies of the world, namely the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the urological disorders market, including market size, the annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various Phases of drug development.
- Competitive landscape of leading companies. The key companies studied in this report are Johnson & Johnson, Pfizer, GlaxoSmithKline, Astellas Pharma and Sanofi.
- Key M&A activities and licensing agreements that have taken place between 2004 and 2011 in the global urological disorders market.
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Urological Disorders Therapeutics to 2017 - Introduction 13
2.1 GBI Research Report Guidance 14
3 Urological Disorders Therapeutics to 2017 - Market Overview 15
3.1 Introduction 15
3.2 Revenue Forecasts for the Global Urological Disorders Market 16
3.2.1 Revenue 16
3.2.2 Generic Share 17
3.2.3 Annual Cost of Therapy 18
3.2.4 Treatment Usage Patterns 20
3.3 Urological Disorders Market Drivers and Restraints 26
3.3.1 Urological Disorders Market Drivers 26
3.3.2 Urological Disorders Market Restraints 27
4 Urological Disorders Therapeutics to 2017 - Geographical Landscape 28
4.1 Revenue by Geography 28
4.2 The US 30
4.2.1 Revenue 30
4.2.2 Annual Cost of Therapy 32
4.2.3 Treatment Usage Patterns 33
4.3 Top Five Countries in Europe 39
4.3.1 Revenue 39
4.3.2 Annual Cost of Therapy 41
4.3.3 Treatment Usage Patterns 42
4.4 Japan 48
4.4.1 Revenue 48
4.4.2 Annual Cost of Therapy 49
4.4.3 Treatment Usage Patterns 50
5 Urological Disorders Therapeutics to 2017 - Therapeutic Landscape 56
5.1 Benign Prostatic Hyperplasia Market 56
5.1.1 Introduction 56
5.1.2 Treatment Algorithm 56
5.1.3 Revenue 57
5.1.4 Annual Cost of Therapy 60
5.1.5 Treatment Usage Patterns 62
5.2 Urinary Incontinence Market 68
5.2.1 Introduction 68
5.2.2 Treatment Algorithm 69
5.2.3 Revenue 71
5.2.4 Annual Cost of Therapy 74
5.2.5 Treatment Usage Patterns 75
5.3 Urinary Tract Infections Market 81
5.3.1 Introduction 81
5.3.2 Treatment Algorithm 81
5.3.3 Revenue 82
5.3.4 Annual Cost of Therapy 85
5.3.5 Treatment Usage Patterns 86
5.4 Interstitial Cystitis Market 92
5.4.1 Introduction 92
5.4.2 Treatment Algorithm 92
5.4.3 Revenue 93
5.4.4 Annual Cost of Therapy 96
5.4.5 Treatment Usage Patterns 97
6 Urological Disorders Therapeutics to 2017 - Pipeline Product Analysis 103
6.1 Introduction 103
6.2 Product Pipeline by Indication 108
6.2.1 Benign Prostatic Hyperplasia 108
6.2.2 Urinary Incontinence 109
6.2.3 Urinary Tract Infections 110
6.2.4 Interstitial Cystitis 111
6.3 Profiles of Key Late-Stage Drugs in the Urological Disorders Market 112
6.3.1 Benign Prostatic Hyperplasia 112
6.3.2 Urinary Incontinence 114
6.3.3 Urinary Tract Infections 115
6.3.4 Interstitial Cystitis 116
7 Urological Disorders Therapeutics to 2017 - Competitive Landscape 119
7.1 Drugs for Major Urological Disorders 119
7.1.1 Duodart 119
7.1.2 Dutasteride (Avodart) 120
7.1.3 Ditropan (Oxybutynin chloride) 121
7.1.4 Tamsulosin (Flomax, Harnal) 121
7.1.5 Enablex (Darifenacin) 122
7.1.6 Sanctura XR (Trospium Chloride) 123
7.1.7 Doribax (Doripenem) 124
7.1.8 Detrol/Detrol LA (Tolterodine tartrate) 125
7.1.9 Vesicare (Solifenacin Succinate) 125
7.1.10 Alfuzosin (Xatral, Uroxatral) 126
7.1.11 Levaquin (levofloxacin) 127
7.1.12 Toviaz (Fesoterodine Fumarate) 128
7.2 Market Share Analysis 129
7.3 Competitive Profiling 130
7.3.1 Johnson & Johnson 130
7.3.2 Boehringer Ingelheim 131
7.3.3 Astellas Pharma 132
7.3.4 GlaxoSmithKline 133
7.3.5 Pfizer 134
8 Urological Disorders Therapeutics to 2017 - M&A Landscape 135
8.1 Overview 135
8.2 M&A Deals (2004-2011) 136
8.2.1 By Indication 136
8.2.2 By Year 137
8.2.3 By Deal Type 138
8.2.4 By Deal Sub-Type 139
8.2.5 Geography 140
8.2.6 Value 141
8.3 Licensing Deals 143
8.3.1 By Indication 143
8.3.2 By Year 144
8.3.3 By Geography 145
8.3.4 By Value 146
8.4 Co-Development Deals 147
8.4.1 By Indication 147
8.4.2 By Year 148
8.4.3 By Geography 149
8.4.4 By Value 150
9 Urological Disorders Therapeutics to 2017 - Appendix 151
9.1 Market Definitions 151
9.2 Abbreviations 151
9.3 Research Methodology 152
9.3.1 Coverage 152
9.3.2 Secondary Research 153
9.3.3 Primary Research 153
9.3.4 Therapeutic Landscape 154
9.3.5 Market Size by Geography 156
9.3.6 Geographical Landscape 157
9.3.7 Pipeline Analysis 157
9.3.8 Competitive Landscape 157
9.3.9 Expert Panel Validation 157
9.4 Contact Us 157
9.5 Disclaimer 157
9.6 Sources 158
1.1 List of Tables
Table 1: Urological Disorders Therapeutics to 2017, Global, Revenue ($bn), 2002-2010 16
Table 2: Urological Disorders Therapeutics to 2017, Global, Revenue Forecasts ($bn), 2010-2017 16
Table 3: Urological Disorders Therapeutics to 2017, Global, Branded Vs Generics ($bn), 2002-2010 17
Table 4: Urological Disorders Therapeutics to 2017, Global, Branded Vs Generics ($bn), 2010-2017 18
Table 5: Urological Disorders Therapeutics to 2017, Global, Annual Cost of Therapy ($), 2002-2010 19
Table 6: Urological Disorders Therapeutics to 2017, Global, Annual Cost of Therapy ($), 2010-2017 19
Table 7: Urological Disorders Therapeutics to 2017, Therapeutic Usage Patterns (million), 2002-2010 20
Table 8: Urological Disorders Therapeutics to 2017, Therapeutic Usage Patterns (million), 2010-2017 21
Table 9: Urological Disorders Therapeutics to 2017, Global, Revenue by Geography, ($bn), 2002-2010 29
Table 10: Urological Disorders Therapeutics to 2017, Global, Revenue by Geography, ($bn), 2010-2017 29
Table 11: Urological Disorders Therapeutics to 2017, The US, Revenue ($bn), 2002-2010 30
Table 12: Urological Disorders Therapeutics to 2017, The US, Revenue Forecasts ($bn), 2010-2017 31
Table 13: Urological Disorders Therapeutics to 2017, The US, Annual Cost of Therapy ($), 2002-2010 32
Table 14: Urological Disorders Therapeutics to 2017, The US, Annual Cost of Therapy ($), 2010-2017 32
Table 15: Urological Disorders Therapeutics to 2017, The US, Therapeutic Usage Patterns (million), 2002-2010 34
Table 16: Urological Disorders Therapeutics to 2017, The US, Therapeutic Usage Patterns (million), 2010-2017 34
Table 17: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Revenue ($m), 2002-2010 39
Table 18: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 40
Table 19: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 41
Table 20: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 41
Table 21: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Therapeutic Usage Patterns (million), 2002-2010 43
Table 22: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Therapeutic Usage Patterns (million), 2010-2017 43
Table 23: Urological Disorders Therapeutics to 2017, Japan, Revenue ($m), 2002-2010 48
Table 24: Urological Disorders Therapeutics to 2017, Japan, Revenue Forecasts ($m), 2010-2017 48
Table 25: Urological Disorders Therapeutics to 2017, Japan, Annual Cost of Therapy ($), 2002-2010 49
Table 26: Urological Disorders Therapeutics to 2017, Japan, Annual Cost of Therapy ($), 2010-2017 50
Table 27: Urological Disorders Therapeutics to 2017, Japan, Therapeutic Usage Patterns (million), 2002-2010 51
Table 28: Urological Disorders Therapeutics to 2017, Japan, Therapeutic Usage Patterns (million), 2010-2017 51
Table 29: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Revenue ($bn), 2002-2010 58
Table 30: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Revenue Forecasts ($bn), 2010-2017 58
Table 31: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Branded Vs Generics ($bn), 2002-2010 59
Table 32: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Branded Vs Generics ($bn), 2010-2017 59
Table 33: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Annual Cost of Therapy ($), 2002-2010 60
Table 34: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Annual Cost of Therapy ($), 2010-2017 61
Table 35: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Treatment Usage Patterns (million), 2002-2010 62
Table 36: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Treatment Usage Patterns (million), 2010-2017 63
Table 37: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Revenue ($bn), 2002-2010 71
Table 38: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Revenue Forecasts ($bn), 2010-2017 71
Table 39: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Branded Vs Generics ($m), 2002-2010 72
Table 40: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Branded Vs Generics ($m), 2010-2017 73
Table 41: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Annual Cost of Therapy ($), 2002-2010 74
Table 42: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Annual Cost of Therapy ($), 2010-2017 74
Table 43: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Treatment Usage Patterns (million), 2002-2010 75
Table 44: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Treatment Usage Patterns (million), 2010-2017 76
Table 45: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Revenue ($bn), 2002-2010 82
Table 46: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Revenue Forecasts ($bn), 2010-2017 83
Table 47: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Branded Vs Generics ($bn), 2002-2010 84
Table 48: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Branded Vs Generics ($bn), 2010-2017 84
Table 49: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Annual Cost of Therapy ($), 2002-2010 85
Table 50: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Annual Cost of Therapy ($), 2010-2017 85
Table 51: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Treatment Usage Patterns (million), 2002-2010 86
Table 52: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Treatment Usage Patterns (million), 2010-2017 87
Table 53: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Revenue ($m), 2002-2010 93
Table 54: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Revenue Forecasts ($m), 2010-2017 94
Table 55: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Branded Vs Generics ($m), 2002-2010 95
Table 56: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Branded Vs Generics ($m), 2010-2017 95
Table 57: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Annual Cost of Therapy ($), 2002-2010 96
Table 58: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Annual Cost of Therapy ($), 2010-2017 96
Table 59: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Treatment Usage Patterns ('000), 2002-2010 97
Table 60: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Treatment Usage Patterns ('000), 2010-2017 98
Table 61: Urological Disorders Therapeutics to 2017, Pipeline Products, 2010 105
Table 62: Urological Disorders Therapeutics to 2017, Key Pipeline Products, Mechanism of Action, 2010 107
Table 63: Urological Disorders Therapeutics to 2017, Global, Number of Deals by Indication, 2004-2011 135
Table 64: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Indication, 2004-2011 136
Table 65: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals, 2004-2011 137
Table 66: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Deal Type, 2004-2011 138
Table 67: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Deal Sub-Type, 2004-2011 139
Table 68: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Geography, 2004-2011 140
Table 69: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Value, 2004-2011 141
Table 70: Urological Disorders Therapeutics to 2017, Global, Top Five M&A Deals, 2005-2011 142
Table 71: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements by Indication, 2004-2011 143
Table 72: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements, 2004-2011 144
Table 73: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements by Geography, 2004-2011 145
Table 74: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements by Value, 2004-2011 146
Table 75: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals by Indication, 2004-2010 147
Table 76: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals, 2004-2010 148
Table 77: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals by Geography, 2004-2010 149
Table 78: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals by Value, 2004-2010 150
1.2 List of Figures
Figure 1: Urological Disorders Therapeutics to 2017, Global, Share of Major Urological Disorders, Revenue(%), 2010 15
Figure 2: Urological Disorders Therapeutics to 2017, Global, Revenue Forecasts ($bn), 2002-2017 16
Figure 3: Urological Disorders Therapeutics to 2017, Global, Branded Vs Generics ($bn), 2002-2017 17
Figure 4: Urological Disorders Therapeutics to 2017, Global, Annual Cost of Therapy ($), 2002-2017 18
Figure 5: Urological Disorders Therapeutics to 2017, Therapeutic Usage Patterns (million), 2002-2017 20
Figure 6: Urological Disorders Therapeutics to 2017, Diseased Population (million), 2002-2017 22
Figure 7: Urological Disorders Therapeutics to 2017, Treatment Seeking Population (million), 2002-2017 23
Figure 8: Urological Disorders Therapeutics to 2017, Diagnosis Population (million), 2002-2017 24
Figure 9: Urological Disorders Therapeutics to 2017, Prescription Population (million), 2002-2017 25
Figure 10: Urological Disorders Therapeutics to 2017, Global, Drivers and Restraints, 2010 26
Figure 11: Urological Disorders Therapeutics to 2017, Global, Revenue by Geography, ($bn), 2010 28
Figure 12: Urological Disorders Therapeutics to 2017, The US, Revenue Forecasts ($bn), 2002-2017 30
Figure 13: Urological Disorders Therapeutics to 2017, The US, Annual Cost of Therapy ($), 2002-2017 32
Figure 14: Urological Disorders Therapeutics to 2017, The US, Therapeutic Usage Patterns (million), 2002-2017 33
Figure 15: Urological Disorders Therapeutics to 2017, The US, Diseased Population (million), 2002-2017 35
Figure 16: Urological Disorders Therapeutics to 2017, The US, Treatment Seeking Population (million), 2002-2017 36
Figure 17: Urological Disorders Therapeutics to 2017, The US, Diagnosis Population (million), 2002-2017 37
Figure 18: Urological Disorders Therapeutics to 2017, The US, Prescription Population (million), 2002-2017 38
Figure 19: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 39
Figure 20: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 41
Figure 21: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Therapeutic Usage Patterns (million), 2002-2017 42
Figure 22: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Diseased Population (million), 2002-2017 44
Figure 23: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Treatment Seeking Population (million), 2002-2017 45
Figure 24: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Diagnosis Population (million), 2002-2017 46
Figure 25: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Prescription Population (million), 2002-2017 47
Figure 26: Urological Disorders Therapeutics to 2017, Japan, Revenue Forecasts ($m), 2002-2017 48
Figure 27: Urological Disorders Therapeutics to 2017, Japan, Annual Cost of Therapy ($), 2002-2017 49
Figure 28: Urological Disorders Therapeutics to 2017, Japan, Therapeutic Usage Patterns (million), 2002-2017 50
Figure 29: Urological Disorders Therapeutics to 2017, Japan, Diseased Population (million), 2002-2017 52
Figure 30: Urological Disorders Therapeutics to 2017, Japan, Treatment Seeking Population (million), 2002-2017 53
Figure 31: Urological Disorders Therapeutics to 2017, Japan, Diagnosis Population (million), 2002-2017 54
Figure 32: Urological Disorders Therapeutics to 2017, Japan, Prescription Population (million), 2002-2017 55
Figure 33: Urological Disorders Therapeutics to 2017, BPH Treatment Algorithm 56
Figure 34: Urological Disorders Therapeutics to 2017, Global, BPH Revenue Forecasts ($bn), 2002-2017 57
Figure 35: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Branded Vs Generics ($bn), 2002-2017 59
Figure 36: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Annual Cost of Therapy ($), 2002-2017 60
Figure 37: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Treatment Usage Patterns (million), 2002-2017 62
Figure 38: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Diseased Population (million), 2002-2017 64
Figure 39: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Treatment Seeking Population (million), 2002-2017 65
Figure 40: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Diagnosis Population (million), 2002-2017 66
Figure 41: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Prescription Population (million), 2002-2017 67
Figure 42: Urological Disorders Therapeutics to 2017, Urinary Incontinence Treatment Algorithm Part 1 69
Figure 43: Urological Disorders Therapeutics to 2017, Urinary Incontinence Treatment Algorithm, Part-2 70
Figure 44: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Revenue Forecasts ($bn), 2002-2017 71
Figure 45: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Branded Vs Generics ($m), 2002-2017 72
Figure 46: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Annual Cost of Therapy ($), 2002-2017 74
Figure 47: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Treatment Usage Patterns (million), 2002-2017 75
Figure 48: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Diseased Population (million), 2002-2017 77
Figure 49: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Treatment Seeking Population (million), 2002-2017 78
Figure 50: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Diagnosis Population (million), 2002-2017, 79
Figure 51: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Prescription Population (million), 2002-2017 80
Figure 52: Urological Disorders Therapeutics to 2017, Urinary Tract Infection Treatment Algorithm 81
Figure 53: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Revenue Forecasts ($bn), 2002-2017 82
Figure 54: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Branded Vs Generics ($m), 2002-2017 83
Figure 55: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Annual Cost of Therapy ($), 2002-2017 85
Figure 56: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Treatment Usage Patterns (million), 2002-2017 86
Figure 57: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Diseased Population (million), 2002-2017 88
Figure 58: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Treatment Seeking Population (million), 2002-2017 89
Figure 59: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Diagnosis Population (million), 2002-2017 90
Figure 60: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Prescription Population (million), 2002-2017 91
Figure 61: Urological Disorders Therapeutics to 2017, Interstitial Cystitis Treatment Algorithm 92
Figure 62: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Revenue Forecasts ($m), 2002-2017 93
Figure 63: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Branded Vs Generics ($m), 2002-2017 94
Figure 64: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Annual Cost of Therapy ($), 2002-2017 96
Figure 65: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Treatment Usage Patterns ('000), 2002-2017 97
Figure 66: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Diseased Population (million), 2002-2017 99
Figure 67: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Treatment Seeking Population (million), 2002-2017 100
Figure 68: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Diagnosis Population (million), 2002-2017 101
Figure 69: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Prescription Population (million), 2002-2017 102
Figure 70: Urological Disorders Therapeutics to 2017, Global, R&D Pipeline by Indication (%), 2011 103
Figure 71: Urological Disorders Therapeutics to 2017, Global, R&D Pipeline by Phase (%), 2011 104
Figure 72: Urological Disorders Therapeutics to 2017, R&D Pipeline by Phase in Benign Prostatic Hyperplasia Market (%), 2011 108
Figure 73: Urological Disorders Therapeutics to 2017, R&D Pipeline by Phase in Urinary Incontinence Market (%), 2011 109
Figure 74: Urological Disorders Therapeutics to 2017, R&D Pipeline by Phase in Urinary Tract Infection Market (%), 2011 110
Figure 75: Urological Disorders Therapeutics to 2017, R&D Pipeline by Phase in Interstitial Cystitis Market (%), 2011 111
Figure 76: Urological Disorders Therapeutics to 2017, Global, Market Share of Top Manufacturers (%), 2010 129
Figure 77: Urological Disorders Therapeutics to 2017, SWOT Analysis of Johnson & Johnson, 2011 130
Figure 78: Urological Disorders Therapeutics to 2017, SWOT Analysis of Boehringer Ingelheim, 2011 131
Figure 79: Urological Disorders Therapeutics to 2017, SWOT Analysis of Astellas Pharma, 2011 132
Figure 80: Urological Disorders Therapeutics to 2017, SWOT Analysis of GlaxoSmithKline, 2011 133
Figure 81: Urological Disorders Therapeutics to 2017, SWOT Analysis of Pfizer, 2011 134
Figure 82: Urological Disorders Therapeutics to 2017, Global, Deals by Indication (%), 2004-2011 135
Figure 83: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Indication (%), 2004-2011 136
Figure 84: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals, 2004-2011 137
Figure 85: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Deal Type (%), 2004-2011 138
Figure 86: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Sub Deal Type (%), 2004-2011 139
Figure 87: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Geography (%), 2004-2011 140
Figure 88: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Value (%), 2004-2011 141
Figure 89: Urological Disorders Therapeutics to 2017, Global, Licensing Agreements by Indication (%), 2004-2011 143
Figure 90: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements, 2004-2011 144
Figure 91: Urological Disorders Therapeutics to 2017, Global, Licensing Agreements by Geography (%), 2004-2011 145
Figure 92: Urological Disorders Therapeutics to 2017, Global, Licensing Agreements by Value (%), 2004-2011 146
Figure 93: Urological Disorders Therapeutics to 2017, Global, Co-Development Deals by Indication (%), 2004-2010 147
Figure 94: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals, 2004-2010 148
Figure 95: Urological Disorders Therapeutics to 2017, Global, Co-Development Deals by Geography (%), 2004-2010 149
Figure 96: Urological Disorders Therapeutics to 2017, Global, Co-Developments Deals by Value (%), 2004-2010 150
Figure 97: GBI Research Market Forecasting Model 156
Companies mentioned
Johnson & Johnson
Boehringer Ingelheim
Astellas Pharma
GlaxoSmithKline
Pfizer
To order this report:
Pathology Industry: Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker